Cytokinetics, Inc. Share Price Nasdaq
Equities
US23282W1009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
26/04 | Cytokinetics Appoints Sung Lee as CFO | MT |
26/04 | Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024 | CI |
Sales 2024 * | 10.71M 893M | Sales 2025 * | 152M 12.68B | Capitalization | 6.74B 562B |
---|---|---|---|---|---|
Net income 2024 * | -466M -38.84B | Net income 2025 * | -365M -30.42B | EV / Sales 2024 * | 613 x |
Net cash position 2024 * | 173M 14.41B | Net cash position 2025 * | 546M 45.53B | EV / Sales 2025 * | 40.7 x |
P/E ratio 2024 * |
-14.5
x | P/E ratio 2025 * |
-19.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.42% |
Latest transcript on Cytokinetics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 60 | 01/98/01 |
Kari Loeser
CMP | Compliance Officer | - | 01/21/01 |
Stuart Kupfer
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy Wysenski
BRD | Director/Board Member | 66 | 20/20/20 |
Edward Kaye
BRD | Director/Board Member | 74 | 20/16/20 |
Santo Costa
BRD | Director/Board Member | 78 | 01/10/01 |
1st Jan change | Capi. | |
---|---|---|
-1.65% | 103B | |
+6.75% | 101B | |
+7.13% | 23.07B | |
-12.60% | 22.23B | |
-6.91% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |